Aptevo Therapeutics Inc (APVO)

Overview

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to the research and development of innovative immunotherapeutic treatments for cancer. Established in 2016 and headquartered in Seattle, Washington, Aptevo employs its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies to craft monospecific, bispecific, and multi-specific antibody candidates. These candidates are designed to bolster the human immune system's ability to combat cancer cells, representing a frontier in medical science's ongoing battle against various forms of the disease. The company's dynamic research efforts underscore a commitment to addressing the complexities of cancer through the development of groundbreaking, targeted therapies.

Products and Services

• APVO436: This leading clinical candidate for blood cancer, specifically targeting acute myelogenous leukemia, is currently undergoing a Phase 1b/2 clinical trial. APVO436 epitomizes Aptevo’s approach to developing therapies that engage the body's immune system to fight cancer.
• ALG.APV-527: A novel bispecific ADAPTIR candidate, ALG.APV-527 is in Phase 1 clinical trials. It is aimed at treating non-small cell lung cancer (NSCLC), head and neck, colorectal, pancreatic, breast, and other solid tumors. Developed in collaboration with Alligator Bioscience AB, this investigational product highlights the potential of bispecific antibodies in targeting and neutralizing cancer cells.
• APVO603: Positioned as a preclinical dual agonist bispecific ADAPTIR candidate, APVO603 is designed for the treatment of multiple solid tumors. It showcases Aptevo’s dedication to expanding its portfolio with versatile therapeutic agents capable of addressing a wide range of cancers.
• APVO442: Utilizing the ADAPTIR-FLEX platform technology, APVO442 is a novel bispecific candidate currently in the development stage for multiple solid tumors. This candidate represents the next generation of Aptevo’s commitment to innovation in cancer therapy.
• APVO711: Still in the preclinical phase, APVO711 is a dual mechanism bispecific ADAPTIR candidate focused on treating prostate cancer. Highlighting the company’s exploration into specific cancer types, APVO711 aims to offer a new avenue for battling this prevalent disease.